- 27 Jun 2022
- ICICIdirect Research
Dr Reddy’s acquires injectable product portfolio for USDRREDDY - 4475 Change: 55.60 (1.26 %)
News: Dr Reddy’s has acquired a portfolio of branded and generic injectable products from Eton Pharmaceuticals for an upfront payment of ~ US$5 million in cash, plus contingent payments of up to US$45 million. The portfolio includes the Biorphen Injection and Rezipres Injection NDAs with nine separate combinations of strengths and one first-to-file approved ANDA for Cysteine Hydrochloride for US.
Views: The acquisition will complement Dr Reddy's US institutional business with limited competition injectable products and provides foundational footprint to address products with limited availability. Company's focus will be to integrate the portfolio and grow the business. The value of total addressable market for these products in the US is ~US$174 million (MAT April 2022, IQVIA). Dr Reddy’s is focussed on expansion of US complex portfolio in form of injectables, biosimilars and complex generics.